FDA Expands Imcivree Label to Acquired Hypothalamic Obesity — First Approved Treatment for a Condition Affecting 10,000 Americans
By FieldPulse Staff · March 21, 2026
Tags: fda-approval, obesity, rare-disease, pediatric
Rhythm Pharmaceuticals received FDA approval on March 19 to expand Imcivree's label to include acquired hypothalamic obesity, a severe form of obesity caused by hypothalamic injury — typically from craniopharyngioma treatment. It is the first and only approved therapy for this condition.
Rhythm Pharmaceuticals announced on March 19, 2026 that the FDA approved a new indication for Imcivree (setmelanotide): acquired hypothalamic obesity (AHO) in adults and pediatric patients aged four and older.
No therapy had previously been approved for this indication.
Acquired hypothalamic obesity develops following damage or dysfunction of the hypothalamus — most commonly from craniopharyngioma tumors or their surgical treatment, radiation, or traumatic injury.
The hypothalamic damage disrupts the melanocortin pathway that regulates appetite and energy expenditure, leading to severe, intractable weight gain that does not respond to conventional dietary interventions or standard anti-obesity medications.
The estimated U.S.
patient population is approximately 10,000 people, predominantly pediatric and young adult patients who survived treatment for rare brain tumors.
It is a small but profoundly underserved population with no prior pharmacological options.
The Phase 3 TRANSCEND trial (142 patients) met its primary endpoint, demonstrating a -18.4% placebo-adjusted BMI reduction.
Imcivree works as a melanocortin-4 receptor (MC4R) agonist, bypassing the damaged hypothalamic pathway by directly activating the downstream receptor.
Imcivree was previously approved for three rare genetic obesity conditions caused by POMC, PCSK1, or LEPR deficiencies, where it has demonstrated similar BMI reductions.
This label expansion moves the drug into a larger, surgically-induced obesity population.
What it means for reps: Rhythm's Imcivree field force will now expand its call point universe to include pediatric endocrinologists, neuroendocrinologists, and neurosurgeons who manage craniopharyngioma patients post-treatment.
For a drug already established in rare genetic obesity, this is a meaningful new commercial channel with a high unmet need, strong clinical data, and likely favorable rare-disease payer coverage.